# From Bench to Brain: Translating EV and Nanocarrier Research into Parkinson’s Disease Therapies

## TL;DR

This paper explores how extracellular vesicles and nanocarriers could be used to develop new therapies for Parkinson’s disease by delivering protective molecules to the brain.

## Contribution

The paper highlights the dual role of extracellular vesicles in Parkinson’s disease and emphasizes new nanocarrier systems for improved drug delivery.

## Key findings

- Extracellular vesicles can both spread toxic α-synuclein and provide neuroprotection in Parkinson’s disease.
- Nanocarriers like liposomes are being developed to enhance drug delivery to the brain for PD therapy.
- Scalability and standardization remain major challenges for translating these approaches into clinical treatments.

## Abstract

PD is marked by dopamine-secreting neuron loss, α-synuclein deposition, and chronic brain inflammation, with no disease-stopping or disease-slowing therapies on the horizon. EVs, especially those derived from mesenchymal stem cells, hold promise since they can cross the blood–brain barrier and deliver brain cell-protective molecules. Interestingly, EVs have a dual role in PD: they can spread toxic α-synuclein between cells, but they also can provide neuroprotection by alleviating oxidative stress, modulating inflammation, and enhancing cell survival through autophagy. In parallel, nanocarrier platforms like liposomes and nanoparticles are being designed to improve drug delivery to the brain. Both EVs and nanocarriers, however, are limited by large-scale production, reproducible quality, and translational medicine to the clinic. Combined, these approaches have promising potential for potential PD therapies.

Parkinson’s disease (PD) is a disabling neurodegenerative disorder that is defined by progressive loss of dopaminergic neurons in the substantia nigra, deposition of α-synuclein aggregates, and chronic neuroinflammation. While symptomatic therapies have evolved, disease-modifying therapies remain elusive. Extracellular vesicles (EVs), particularly those derived from mesenchymal stem cells (MSC-EVs), have emerged as promising therapeutic agents because they possess a natural ability to cross the blood–brain barrier and deliver bioactive cargo. Herein, we review the dual-edged function of EVs in PD pathogenesis: facilitating the transfer of toxic α-synuclein while also conferring neuroprotective signals through MSC-EVs. We outline the mechanisms of MSC-EV-mediated neuroprotection that include the regulation of oxidative stress, neuroinflammation, and autophagy. We also emphasize new nanocarrier systems designed to bypass delivery challenges in PD therapy. While preclinical studies are extremely encouraging, significant issues regarding scalability, standardization, and clinical translation must be resolved before realizing the ultimate therapeutic potential of EV-based and nanocarrier-based approaches to PD.